glp 1 agonist schizophrenia In non-obese patients with schizophrenia, antipsychotic-related diabetes may not be about weight at all. A letter in JCP responding to McIntyre's -1 commentary proposes a β-cell–centric view — especially for Asian populations — Reassuring' findings suggest GLP-1 receptor

Description

The synthesis of findings from multiple investigations (Azzam et al., Mitchell et al., Krajnc et al.) fortifies the existing evidence base, enhancing the validity and applicability of the conclusions regarding the benefits of GLP-1 RAs in the management of IIH

Although AOM liraglutide (Saxenda) has been approved for treatment of obesity in adolescents since late 2020 ( 5 ), the approval of AOM semaglutide (Wegovy) in December 2022 for treatment of obesity for adolescents prompted new excitement ( 6 )

While promising, these arent yet widely available and more research is needed to confirm their long-term effectiveness and safety

In this structure, the GLP-1R ECD has rotated slightly relative to the peptide-bound structures, and W33 has moved 14 , closing the top of the small-molecule binding pocket